{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:35Z","timestamp":1787008415220,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007333","name":"Alzheimer's Disease Neuroimaging Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-2-0012"],"award-info":[{"award-number":["W81XWH-12-2-0012"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Araclon Biotech"},{"DOI":"10.13039\/100007742","name":"BioClinica, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007742","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Elan Pharmaceuticals, Inc."},{"name":"Johnson Pharmaceutical Research & Development LLC."},{"name":"Neurotrack Technologies"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Piramal Imaging"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Allelic variation in the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has been shown to moderate rates of cognitive decline in preclinical sporadic Alzheimer\u2019s disease (AD; i.e., A\u03b2\u2009+\u2009older adults), and pre-symptomatic autosomal dominant Alzheimer\u2019s disease (ADAD). In ADAD, Met66 was also associated with greater increases in CSF levels of total-tau (t-tau) and phosphorylated tau (p-tau181). This study sought to determine the extent to which BDNF Val66Met is associated with changes in episodic memory and CSF t-tau and p-tau181 in A\u03b2\u2009+\u2009older adults in early-stage sporadic AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A\u03b2\u2009+\u2009Met66 carriers (n\u2009=\u200994) and Val66 homozygotes (n\u2009=\u2009192) enrolled in the Alzheimer\u2019s Disease Neuroimaging Initiative who did not meet criteria for AD dementia, and with at least one follow-up neuropsychological and CSF assessment, were included. A series of linear mixed models were conducted to investigate changes in each outcome over an average of 2.8\u00a0years, covarying for CSF A\u03b242, APOE \u03b54 status, sex, age, baseline diagnosis, and years of education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A\u03b2\u2009+\u2009Met66 carriers demonstrated significantly faster memory decline (d\u2009=\u20090.33) and significantly greater increases in CSF t-tau (d\u2009=\u20090.30) and p-tau181 (d\u2009=\u20090.29) compared to Val66 homozygotes, despite showing equivalent changes in CSF A\u03b242.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that reduced neurotrophic support, which is associated with Met66 carriage, may increase vulnerability to A\u03b2-related tau hyperphosphorylation, neuronal dysfunction, and cognitive decline even prior to the emergence of dementia. Additionally, these findings highlight the need for neuropsychological and clinicopathological models of AD to account for neurotrophic factors and the genes which moderate their expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/arclin\/acae014","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:44:07Z","timestamp":1708303447000},"page":"683-691","source":"Crossref","is-referenced-by-count":7,"title":["<i>BDNF<\/i>\n                    Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer\u2019s disease"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2327-2372","authenticated-orcid":false,"given":"Diny","family":"Thomson","sequence":"first","affiliation":[{"name":"Turner Institute for Brain and Mental Health , School of Psychological Sciences, , Clayton, VIC 3168 , Australia"},{"name":"Monash University , School of Psychological Sciences, , Clayton, VIC 3168 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rosenich","sequence":"additional","affiliation":[{"name":"Cogstate Ltd , Melbourne, VIC 3000 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maruff","sequence":"additional","affiliation":[{"name":"Turner Institute for Brain and Mental Health , School of Psychological Sciences, , Clayton, VIC 3168 , Australia"},{"name":"Monash University , School of Psychological Sciences, , Clayton, VIC 3168 , Australia"},{"name":"Cogstate Ltd , Melbourne, VIC 3000 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-5156","authenticated-orcid":false,"given":"Yen Ying","family":"Lim","sequence":"additional","affiliation":[{"name":"Turner Institute for Brain and Mental Health , School of Psychological Sciences, , Clayton, VIC 3168 , Australia"},{"name":"Monash University , School of Psychological Sciences, , Clayton, VIC 3168 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"3","key":"2024082600155782200_ref1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nature Medicine"},{"issue":"22","key":"2024082600155782200_ref2","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1212\/WNL.0000000000003980","article-title":"BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention","volume":"88","author":"Boots","year":"2017","journal-title":"Neurology"},{"key":"2024082600155782200_ref3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neurobiolaging.2021.08.018","article-title":"BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: The SCIENCe project","volume":"108","author":"Bosch","year":"2021","journal-title":"Neurobiology of Aging"},{"issue":"9","key":"2024082600155782200_ref4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jalz.2018.04.010","article-title":"Sex, amyloid, and APOE \u03b54 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts","volume":"14","author":"Buckley","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"13","key":"2024082600155782200_ref5","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.1c00181","article-title":"Optimized TrkB agonist ameliorates Alzheimer\u2019s disease pathologies and improves cognitive functions via inhibiting delta-secretase","volume":"12","author":"Chen","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"key":"2024082600155782200_ref6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1037\/14805-018","volume-title":"Methodological issues and strategies in clinical research","author":"Cohen","year":"2016"},{"issue":"3","key":"2024082600155782200_ref7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0149-7634(00)00012-9","article-title":"The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment","volume":"24","author":"Collie","year":"2000","journal-title":"Neuroscience & Biobehavioral Reviews"},{"issue":"1\u20132","key":"2024082600155782200_ref8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0169-328X(97)00125-3","article-title":"Brain-derived neurotrophic factor is reduced in Alzheimer's disease","volume":"49","author":"Connor","year":"1997","journal-title":"Molecular Brain Research"},{"issue":"4","key":"2024082600155782200_ref9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","article-title":"Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","volume":"6","author":"Crane","year":"2012","journal-title":"Brain Imaging and Behavior"},{"issue":"2","key":"2024082600155782200_ref10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","article-title":"The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function","volume":"112","author":"Egan","year":"2003","journal-title":"Cell"},{"issue":"5","key":"2024082600155782200_ref11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1460-9568.2005.04290.x","article-title":"Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3Kinase signalling mechanism","volume":"22","author":"Elliott","year":"2005","journal-title":"European Journal of Neuroscience"},{"issue":"15","key":"2024082600155782200_ref1e","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1523\/JNEUROSCI.6251-09.2010","volume":"30","author":"Erickson","year":"(2010)","journal-title":"Journal of Neuroscience"},{"key":"2024082600155782200_ref12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpsychires.2014.01.019","article-title":"Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease","volume":"53","author":"Faria","year":"2014","journal-title":"Journal of Psychiatric Research"},{"issue":"7","key":"2024082600155782200_ref13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199907000-00007","article-title":"BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies","volume":"58","author":"Ferrer","year":"1999","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"3","key":"2024082600155782200_ref14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"2024082600155782200_ref1f","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cca.2015.05.024","article-title":"Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability","volume":"449","author":"Fourier","year":"(2015)","journal-title":"Clinica Chimica Acta"},{"issue":"2","key":"2024082600155782200_ref15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41380-019-0404-6","article-title":"The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer\u2019s disease","volume":"26","author":"Franzmeier","year":"2021","journal-title":"Molecular Psychiatry"},{"issue":"11","key":"2024082600155782200_ref16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"17","key":"2024082600155782200_ref17","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1523\/JNEUROSCI.23-17-06690.2003","article-title":"Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance","volume":"23","author":"Hariri","year":"2003","journal-title":"Journal of Neuroscience"},{"issue":"5","key":"2024082600155782200_ref18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"2024082600155782200_ref19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jnr.20984","article-title":"Amyloid \u03b2 up-regulates brain-derived neurotrophic factor production from astrocytes: Rescue from amyloid \u03b2-related neuritic degeneration","volume":"84","author":"Kimura","year":"2006","journal-title":"Journal of Neuroscience Research"},{"issue":"4","key":"2024082600155782200_ref20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3233\/JAD-170072","article-title":"Effect of APOE genotype on amyloid deposition, brain volume, and memory in cognitively normal older individuals","volume":"58","author":"Lim","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"issue":"10","key":"2024082600155782200_ref21","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/brain\/aww200","article-title":"BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease","volume":"139","author":"Lim","year":"2016","journal-title":"Brain"},{"issue":"3","key":"2024082600155782200_ref22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.25299","article-title":"Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease","volume":"84","author":"Lim","year":"2018","journal-title":"Annals of Neurology"},{"issue":"5","key":"2024082600155782200_ref23","doi-asserted-by":"crossref","first-page":"e12724","DOI":"10.1111\/gbb.12724","article-title":"BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease","volume":"20","author":"Lim","year":"2021","journal-title":"Genes, Brain and Behavior"},{"issue":"3","key":"2024082600155782200_ref24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamaneurol.2021.5181","article-title":"Association of BDNF Val66Met with tau hyperphosphorylation and cognition in dominantly inherited Alzheimer disease","volume":"79","author":"Lim","year":"2022","journal-title":"JAMA Neurology"},{"issue":"1","key":"2024082600155782200_ref25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/brain\/awt286","article-title":"Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer\u2019s disease","volume":"137","author":"Lim","year":"2014","journal-title":"Brain"},{"issue":"11","key":"2024082600155782200_ref26","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1017\/S1041610217001284","article-title":"BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF","volume":"29","author":"Lim","year":"2017","journal-title":"International Psychogeriatrics"},{"issue":"1","key":"2024082600155782200_ref27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086498","article-title":"Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: A preliminary study","volume":"9","author":"Lim","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"2024082600155782200_ref28","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.neurobiolaging.2013.05.006","article-title":"BDNF Val66Met, A\u03b2 amyloid, and cognitive decline in preclinical Alzheimer's disease","volume":"34","author":"Lim","year":"2013","journal-title":"Neurobiology of Aging"},{"issue":"11","key":"2024082600155782200_ref29","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/mp.2014.123","article-title":"APOE and BDNF polymorphisms moderate amyloid \u03b2-related cognitive decline in preclinical Alzheimer's disease","volume":"20","author":"Lim","year":"2015","journal-title":"Molecular Psychiatry"},{"issue":"6","key":"2024082600155782200_ref30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrn3505","article-title":"BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases","volume":"14","author":"Lu","year":"2013","journal-title":"Nature Reviews Neuroscience"},{"issue":"4","key":"2024082600155782200_ref31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0306-4522(98)00219-X","article-title":"An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease","volume":"88","author":"Murer","year":"1999","journal-title":"Neuroscience"},{"issue":"3","key":"2024082600155782200_ref32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"issue":"11","key":"2024082600155782200_ref33","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"\u03b2-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"issue":"3","key":"2024082600155782200_ref34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"The American Journal of Human Genetics"},{"key":"2024082600155782200_ref35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neurobiolaging.2016.08.020","article-title":"Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease","volume":"48","author":"Rosa","year":"2016","journal-title":"Neurobiology of Aging"},{"issue":"11","key":"2024082600155782200_ref36","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"The American Journal of Psychiatry."},{"key":"2024082600155782200_ref37","volume-title":"Rey auditory verbal learning test: A handbook (Vol. 17)","author":"Schmidt","year":"1996"},{"issue":"4","key":"2024082600155782200_ref38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Annals of Neurology"},{"issue":"3","key":"2024082600155782200_ref39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.14336\/AD.2017.0717","article-title":"BDNF polymorphism: A review of its diagnostic and clinical relevance in neurodegenerative disorders","volume":"9","author":"Shen","year":"2018","journal-title":"Aging and Disease"},{"issue":"5","key":"2024082600155782200_ref40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1017\/S1355617706060863","article-title":"Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease","volume":"12","author":"Twamley","year":"2006","journal-title":"Journal of the International Neuropsychological Society"},{"key":"2024082600155782200_ref41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4612-2294-1_3","volume-title":"Linear mixed models in practice","author":"Verbeke","year":"1997"},{"issue":"4","key":"2024082600155782200_ref42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"15","key":"2024082600155782200_ref43","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.7150\/thno.44165","article-title":"Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"issue":"18","key":"2024082600155782200_ref44","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1073\/pnas.1901348116","article-title":"Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer\u2019s disease pathologies","volume":"116","author":"Xiang","year":"2019","journal-title":"Proceedings of the National Academy of Sciences"}],"container-title":["Archives of Clinical Neuropsychology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/acn\/article-pdf\/39\/6\/683\/58911529\/acae014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/acn\/article-pdf\/39\/6\/683\/58911529\/acae014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T20:17:28Z","timestamp":1724617048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/acn\/article\/39\/6\/683\/7624047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/arclin\/acae014","relation":{},"ISSN":["1873-5843"],"issn-type":[{"value":"1873-5843","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,7]]}}}